2023年欧洲肿瘤内科学会乳腺癌会议(ESMO Breast Cancer 2023) 将于5 月 11 日至 13 日以线上线下相结合的形式在德国柏林举行。大会官网已公布了本次会议的详细日程,【肿瘤资讯】为您整理了中国学者的研究壁报,与您抢先共享本次大会的“中国之声”。
Poster Display session
时间:2023.05.12 12:15 - 13:00
摘要号:9P
基线中性粒细胞/淋巴细胞比值在HER2阳性转移性乳腺癌中的预后价值:CLEOPATRA试验的探索性分析
英文标题:Prognostic Value of Baseline Neutrophil/Lymphocyte Ratio in HER2-Positive Metastatic Breast Cancer: Exploratory analysis from the CLEOPATRA trial
讲者:肖志 (中南大学湘雅医院)
摘要号:60P
基于深度学习的数字病理学用于不典型导管增生/导管原位癌的风险分层
英文标题:Deep learning-based digital pathology for risk stratification of atypical ductal hyperplasia/ductal carcinoma in situ
讲者:Chung-Yen Huang (中国国立台湾大学医学院)
摘要号:107P
MonarchE研究:阿贝西利联合内分泌辅助治疗高危HR+/HER2-早期乳腺癌中国患者预设总生存期中期分析结果
英文标题:Results in Chinese patients from pre-planned overall survival interim analysis in monarchE: abemaciclib plus adjuvant endocrine therapy for high risk HR+, HER2- early breast cancer
讲者:邵志敏 (复旦大学附属肿瘤医院)
摘要号: 111P
乳腺癌治疗中,戈舍瑞林3个月剂型不劣效于1个月剂型:一项真实世界证据研究
英文标题:Goserelin 3 monthly depot is noninferior to Goserelin monthly depot in the treatment of Breast Cancer: A Real-World Evidence Study
讲者:Hao Wu (中山大学肿瘤防治中心)
摘要号:119TiP
在中国 HER2 阳性早期乳腺癌患者中探索奈拉替尼治疗模式的多中心、开放性、单臂、非干预性临床试验:NER-Tree研究
英文标题:A multicenter, open-label, single-arm, non-interventional real-world study to investigate the treatment patterns of Neratinib in HER2-positive early breast cancer (EBC) in China: NER-Tree study
讲者:王晓稼 (中国科学院大学附属肿瘤医院)
摘要号:141P
HR+/HER2-乳腺癌化疗同步新辅助内分泌治疗的系统评价和荟萃分析
英文标题:Concurrent neoadjuvant endocrine therapy with chemotherapy in HR+HER2- breast cancer: a systematic review and meta-analysis
讲者:Lv Wenjie (上海交通大学医学院)
摘要号:157P
接受对侧预防性乳房切除术与单侧乳房切除术的年轻乳腺癌患者的生存结局比较
英文标题:Comparison of Survival Outcomes in Young Patients with Breast Cancer Receiving Contralateral Prophylactic Mastectomy Versus Unilateral Mastectomy
讲者:Hong bo Huang (重庆医科大学)
摘要号:173P
饮食、遗传易感性与乳腺癌风险:来自英国生物样本库的一项队列研究
英文标题:Diet, genetic predisposition and the risk of breast cancer: a cohort study from the UK biobank
讲者:Pingxiu Zhu (福建医科大学)
摘要号:184P
PGS000508是台湾人群乳腺癌风险的预测指标
英文标题:PGS000508 as a Prediction for Breast Cancer Risk in Taiwanese Populations
讲者:Yi-Hsuan Lin (中国台中荣民总医院)
摘要号:207P
转移性 HER2 阴性乳腺癌患者口服长春瑞滨和卡培他滨 (mNC) 的二联节拍化疗方案:中国前瞻性2期研究
英文标题:A doublet metronomic chemotherapeutic regimen with oral vinorelbine and capecitabine (mNC) in patients with metastatic HER2-negative breast cancer: A prospective phase 2 study in China
讲者:Yue Chai (中国医学科学院北京协和医学院)
摘要号:244P
艾立布林在一线/二线紫杉烷类治疗不耐受的中国晚期乳腺癌患者中的应用:患者报告结局
英文标题:Eribulin in Chinese advanced breast cancer patient intolerant to first/second-line taxane-based therapy: the patient-reported outcomes
讲者:罗婷 (四川大学华西医院)
点击下方链接,查看全部壁报研究:https://cslide.ctimeetingtech.com/breast23hybrid/attendee/confcal/session/list?r=st%7E14
排版编辑:肿瘤资讯-Paine